Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03104842
What this trial is testing

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Who this might be right for
Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf 246
Not applicableUnknownNCT06258629
What this trial is testing

Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Who this might be right for
Hematological Malignancies
Sohag University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06880393
What this trial is testing

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 40
Testing effectiveness (Phase 2)Study completedNCT01083316
What this trial is testing

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Who this might be right for
Amyloidosis
Boston Medical Center 35
Testing effectiveness (Phase 2)Study completedNCT03398200
What this trial is testing

Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma

Who this might be right for
Myeloma
Omar Aljitawi 99
Large-scale testing (Phase 3)Study completedNCT00003938
What this trial is testing

Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients

Who this might be right for
Cancer
European Organisation for Research and Treatment of Cancer - EORTC 115
Large-scale testing (Phase 3)Looking for participantsNCT05665140
What this trial is testing

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma
University Hopsital Schleswig Holstein Campus Lübeck 100
Testing effectiveness (Phase 2)Study completedNCT00306735
What this trial is testing

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Who this might be right for
Multiple Myeloma
Eisai Inc. 75
Testing effectiveness (Phase 2)Study completedNCT00281983
What this trial is testing

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Who this might be right for
Chronic Lymphocytic Leukemia
German CLL Study Group 100
Testing effectiveness (Phase 2)UnknownNCT05422027
What this trial is testing

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Xia Zhongjun 42
Testing effectiveness (Phase 2)Study completedNCT00533923
What this trial is testing

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Who this might be right for
AMLALLCLL+6 more
Beth Israel Deaconess Medical Center 25
Early research (Phase 1)Study completedNCT00003962
What this trial is testing

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not applicableStudy completedNCT04028479
What this trial is testing

The Registry of Oncology Outcomes Associated With Testing and Treatment

Who this might be right for
AdenocarcinomaAdenocystic CarcinomaAnal Cancer+73 more
Taproot Health 167
Not applicableNot Yet RecruitingNCT07045168
What this trial is testing

Risk-adapted Therapeutic Strategy in +1q NDMM

Who this might be right for
Multiple Myeloma
FengYan Jin 200
Testing effectiveness (Phase 2)Study completedNCT01432600
What this trial is testing

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Who this might be right for
Myeloma
H. Lee Moffitt Cancer Center and Research Institute 80
Testing effectiveness (Phase 2)Study completedNCT00427765
What this trial is testing

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Who this might be right for
Multiple MyelomaLymphoma
M.D. Anderson Cancer Center 168
Testing effectiveness (Phase 2)Ended earlyNCT00637767
What this trial is testing

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
University of Southampton 25
Testing effectiveness (Phase 2)WithdrawnNCT02402725
What this trial is testing

Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Boston Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT00615589
What this trial is testing

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
University of Michigan Rogel Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT02145403
What this trial is testing

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Who this might be right for
Hematologic MalignanciesRelapseGraft-Versus-Host Disease
University of Michigan Rogel Cancer Center 53
Next Page